MX369666B - Composicion farmaceutica que contiene un derivado de dihidroquinazolina antiviralmente activo. - Google Patents
Composicion farmaceutica que contiene un derivado de dihidroquinazolina antiviralmente activo.Info
- Publication number
- MX369666B MX369666B MX2014010364A MX2014010364A MX369666B MX 369666 B MX369666 B MX 369666B MX 2014010364 A MX2014010364 A MX 2014010364A MX 2014010364 A MX2014010364 A MX 2014010364A MX 369666 B MX369666 B MX 369666B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical preparation
- preparation containing
- antivirally active
- dihydroquinazoline derivative
- dihydroquinazoline
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- NTURVSFTOYPGON-UHFFFAOYSA-N Dihydroquinazoline Chemical class C1=CC=C2C=NCNC2=C1 NTURVSFTOYPGON-UHFFFAOYSA-N 0.000 title 1
- FWYSMLBETOMXAG-UHFFFAOYSA-N 2-[8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetic acid Chemical compound COC1=CC=CC(N2CCN(CC2)C=2N(C(CC(O)=O)C3=CC=CC(F)=C3N=2)C=2C(=CC=C(C=2)C(F)(F)F)OC)=C1 FWYSMLBETOMXAG-UHFFFAOYSA-N 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 241000701022 Cytomegalovirus Species 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 239000012752 auxiliary agent Substances 0.000 abstract 1
- 229940097362 cyclodextrins Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102012101680A DE102012101680A1 (de) | 2012-02-29 | 2012-02-29 | Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat |
| PCT/EP2013/054114 WO2013127970A1 (de) | 2012-02-29 | 2013-02-28 | Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014010364A MX2014010364A (es) | 2014-12-05 |
| MX369666B true MX369666B (es) | 2019-11-14 |
Family
ID=47757622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014010364A MX369666B (es) | 2012-02-29 | 2013-02-28 | Composicion farmaceutica que contiene un derivado de dihidroquinazolina antiviralmente activo. |
Country Status (37)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10319612A1 (de) | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| LT3010891T (lt) * | 2013-06-19 | 2019-08-26 | Aicuris Anti-Infective Cures Gmbh | Amorfinis letermoviras ir jo kietos farmacinės kompozicijos, skirtos peroraliniam įvedimui |
| AU2017274722A1 (en) | 2016-06-03 | 2019-01-17 | Atreya Innovations Private Limited | A device for the detection and reliable capturing of the pulse characteristics |
| MA47743A (fr) * | 2017-03-06 | 2020-01-15 | Venatorx Pharmaceuticals Inc | Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations |
| UY39099A (es) * | 2020-02-27 | 2021-08-31 | Aic246 Gmbh & Co Kg | 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo |
| AR121438A1 (es) * | 2020-02-27 | 2022-06-08 | Aic246 Gmbh & Co Kg | Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio |
| CN114539085B (zh) * | 2020-11-26 | 2023-10-20 | 山东诚创蓝海医药科技有限公司 | 一种脲基衍生物的制备 |
| CN115403528B (zh) * | 2021-05-27 | 2025-01-07 | 南京正大天晴制药有限公司 | 无定形3,4-二氢喹唑啉衍生物的制备方法 |
| CN113880776B (zh) * | 2021-11-16 | 2023-06-16 | 山东诚创蓝海医药科技有限公司 | 一种莱特莫韦中间体的制备方法 |
| AR128035A1 (es) | 2021-12-21 | 2024-03-20 | Aic246 Ag & Co Kg | Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio |
| KR20230126654A (ko) * | 2022-02-23 | 2023-08-30 | 주식회사 엘지화학 | 이소옥사졸린 유도체를 포함하는 주사용 제제 및 이의 제조방법 |
| CN115322157B (zh) * | 2022-06-02 | 2023-12-05 | 浙江车头制药股份有限公司 | 来特莫韦中间体化合物及其制备方法和应用 |
| CN115677539B (zh) * | 2022-11-01 | 2023-10-24 | 南京工业大学 | 一种温和条件下钴催化脲基导向芳烃的高选择性单烯基化的方法 |
| CN119015222A (zh) * | 2024-08-28 | 2024-11-26 | 石家庄四药有限公司 | 一种来特莫韦注射液及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1242699A (en) * | 1985-02-01 | 1988-10-04 | Bristol-Myers Company | Cefbuperazone and derivatives thereof |
| FR2585705B1 (fr) * | 1985-08-05 | 1989-01-13 | Bristol Myers Co | Sels de cephalosporine et compositions injectables |
| JP3552240B2 (ja) * | 1993-02-23 | 2004-08-11 | 第一製薬株式会社 | 高濃度ｔｃｆ製剤 |
| JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
| IT1304190B1 (it) * | 1998-12-18 | 2001-03-08 | Euphar Group Srl | Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche |
| DE60010448T2 (de) * | 1999-03-17 | 2005-04-07 | Astrazeneca Ab | Amid-derivate |
| AU2000249111A1 (en) | 2000-05-30 | 2001-12-11 | Dr. Reddy's Research Foundation | New pharmaceutical composition and the process for its preparation |
| DE10319612A1 (de) * | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| EP1689724B1 (en) * | 2003-11-25 | 2011-12-21 | Novartis AG | Quinazolinone compounds as anticancer agents |
| DE602006004964D1 (de) | 2005-02-10 | 2009-03-12 | Bristol Myers Squibb Co | Dihydrochinazolinone als 5ht-modulatoren |
| DE102005027517A1 (de) | 2005-06-15 | 2006-12-21 | Bayer Healthcare Ag | Verfahren zur Herstellung von Dihydrochinazolinen |
| US8743287B2 (en) * | 2009-07-24 | 2014-06-03 | Broadcom Corporation | Method and system for mitigating motion trail artifacts and improving low contrast contours in temporal filtering based noise reduction |
-
2012
- 2012-02-29 DE DE102012101680A patent/DE102012101680A1/de not_active Ceased
-
2013
- 2013-02-28 KR KR1020147023803A patent/KR102149561B1/ko active Active
- 2013-02-28 SI SI201331541T patent/SI2819648T1/sl unknown
- 2013-02-28 RS RSP20191076 patent/RS59157B1/sr unknown
- 2013-02-28 HR HRP20240197TT patent/HRP20240197T1/hr unknown
- 2013-02-28 ES ES19176985T patent/ES2972133T3/es active Active
- 2013-02-28 HU HUE13707000A patent/HUE045949T2/hu unknown
- 2013-02-28 PH PH1/2014/501937A patent/PH12014501937B1/en unknown
- 2013-02-28 SM SM20240068T patent/SMT202400068T1/it unknown
- 2013-02-28 BR BR112014020946-4A patent/BR112014020946B1/pt active IP Right Grant
- 2013-02-28 IN IN1892MUN2014 patent/IN2014MN01892A/en unknown
- 2013-02-28 EA EA201400963A patent/EA026584B1/ru unknown
- 2013-02-28 ME MEP-2019-219A patent/ME03448B/me unknown
- 2013-02-28 WO PCT/EP2013/054114 patent/WO2013127970A1/de active Application Filing
- 2013-02-28 CN CN201380011670.7A patent/CN104144678A/zh active Pending
- 2013-02-28 RS RS20240135A patent/RS65137B1/sr unknown
- 2013-02-28 US US14/381,290 patent/US10603384B2/en active Active
- 2013-02-28 MX MX2014010364A patent/MX369666B/es active IP Right Grant
- 2013-02-28 ES ES13707000T patent/ES2741698T3/es active Active
- 2013-02-28 UA UAA201410519A patent/UA111415C2/uk unknown
- 2013-02-28 PL PL13707000T patent/PL2819648T3/pl unknown
- 2013-02-28 SM SM20190458T patent/SMT201900458T1/it unknown
- 2013-02-28 AU AU2013224947A patent/AU2013224947B2/en active Active
- 2013-02-28 CA CA2865203A patent/CA2865203C/en active Active
- 2013-02-28 JP JP2014559233A patent/JP6387486B2/ja active Active
- 2013-02-28 SG SG11201405294XA patent/SG11201405294XA/en unknown
- 2013-02-28 PL PL19176985.0T patent/PL3556350T3/pl unknown
- 2013-02-28 EP EP19176985.0A patent/EP3556350B1/de active Active
- 2013-02-28 HR HRP20191369 patent/HRP20191369T1/hr unknown
- 2013-02-28 PT PT191769850T patent/PT3556350T/pt unknown
- 2013-02-28 DK DK19176985.0T patent/DK3556350T3/da active
- 2013-02-28 NZ NZ628444A patent/NZ628444A/en unknown
- 2013-02-28 EP EP13707000.9A patent/EP2819648B1/de active Active
- 2013-02-28 SI SI201332077T patent/SI3556350T1/sl unknown
- 2013-02-28 MY MYPI2014002461A patent/MY172310A/en unknown
- 2013-02-28 HU HUE19176985A patent/HUE065553T2/hu unknown
- 2013-02-28 PT PT13707000T patent/PT2819648T/pt unknown
- 2013-02-28 EP EP24150976.9A patent/EP4328218A3/de active Pending
- 2013-02-28 FI FIEP19176985.0T patent/FI3556350T3/fi active
- 2013-02-28 LT LTEP13707000.9T patent/LT2819648T/lt unknown
- 2013-02-28 LT LTEP19176985.0T patent/LT3556350T/lt unknown
- 2013-02-28 DK DK13707000.9T patent/DK2819648T3/da active
- 2013-02-28 CN CN201910661203.8A patent/CN110433166A/zh active Pending
-
2014
- 2014-08-08 TN TNP2014000345A patent/TN2014000345A1/fr unknown
- 2014-08-13 ZA ZA2014/05949A patent/ZA201405949B/en unknown
- 2014-08-28 CO CO14189543A patent/CO7061076A2/es unknown
- 2014-08-28 IL IL234363A patent/IL234363B/en active IP Right Grant
- 2014-08-29 CL CL2014002306A patent/CL2014002306A1/es unknown
- 2014-09-17 MA MA37360A patent/MA35941B1/fr unknown
-
2019
- 2019-08-20 CY CY20191100885T patent/CY1121910T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000345A1 (en) | Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative | |
| SG10201804552WA (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
| IN2014DN09434A (forum.php) | ||
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| WO2014028589A3 (en) | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| PH12015501964B1 (en) | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c | |
| EP4548972A3 (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
| MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| BR112015000704A2 (pt) | imidazotriazinacarbonitrilas úteis como inibidores de quinase | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| PH12014501967A1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| JO3122B1 (ar) | مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية | |
| NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
| UA112549C2 (uk) | Частинки на основі поліакрилату, що містять активну сполуку | |
| MX344846B (es) | Combinacion de granulos cargados activos con activos adicionales. | |
| BR112014021497A2 (pt) | sistema de entrega de fármaco baseado em jcv-vlp | |
| MX357888B (es) | Sales basicas de adicion de nitroxolina y usos de las mismas. | |
| GEP20156332B (en) | Pyrazoles as crth2 antagonists | |
| PH12015502717A1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| WO2012123924A3 (en) | Antimicrobial composition including at least one or more aggregation(s) silver particles | |
| WO2014104989A8 (en) | Pharmaceutical compositions comprising aripiprazole | |
| TH103144B (th) | องค์ประกอบทางเภสัชกรรมที่มีอนุพันธ์ไดไฮโดรควิแนโซลีนซึ่งออกฤทธิ์ต่อต้านไวรัส | |
| HK1205511A1 (zh) | 二氢喹唑啉衍生物的苯磺酸盐和甲苯磺酸盐及它们作为抗病毒剂的用途 | |
| HK1205509A1 (zh) | 二氢喹唑啉衍生物的钠化和钙化盐及它们用作抗病毒媒介的使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: AICURIS ANTI-INFECTIVE CURES GMBH |
|
| FG | Grant or registration |